title: Pars plana vitrectomy for vitreous opacity associated with ocular sarcoidosis resistant to medical treatment.
abstract: OBJECTIVE
  To examine the results of pars plana vitrectomy for nonclearing vitreous opacities associated with ocular sarcoidosis that is resistant to corticosteroid treatment.
  
  
  METHODS
  Eight consecutive patients (11 eyes) with vitreous opacities and uveitis associated with sarcoidosis were studied. All patients were resistant to or intolerant of corticosteroid therapy. All eyes underwent pars plana vitrectomy, followed by evaluation of visual acuity and recording of the grade of inflammation and complications.
  
  
  RESULTS
  Seven eyes had gained two or more lines of Snellen visual acuity six months postoperatively; visual acuity remained unchanged in the other four eyes. Vitreous inflammation was reduced in all cases. Severe postoperative inflammation did not recur in any eyes. Five eyes developed visually significant cataracts and underwent cataract extraction and intraocular lens insertion within 8-30 months. Based on slit-lamp biomicroscopy and fluorescein angiography, preoperative cystoid macular edema in five eyes resolved or improved within six months after vitrectomy. Postoperative complications included elevated intraocular pressure in three eyes, cataract formation in six eyes, epiretinal membrane formation in one eye, and choroidal neovascularization in one eye. None of the patients developed cystoid macular edema postoperatively. Only three patients received systemic corticosteroids after surgery. At the final visit, only one patient required systemic corticosteroid therapy.
  
  
  CONCLUSIONS
  Pars plana vitrectomy appears to have beneficial effects on restoring vision, stabilizing vitreous inflammation, and reducing systemic corticosteroid requirements in eyes with thick vitreous opacities associated with sarcoidosis that is resistant to medical treatment.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. kiryu@kuhp.kyoto-u.ac.jp
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ieki
authors.forename: Junichi
authors.initials: J
authors.lastname: Kiryu
authors.forename: Mihori
authors.initials: M
authors.lastname: Kita
authors.forename: Teruyo
authors.initials: T
authors.lastname: Tanabe
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamashiro
authors.forename: Noriko
authors.initials: N
authors.lastname: Miyamoto
authors.forename: Shinji
authors.initials: S
authors.lastname: Miura
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Honda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004351:Drug Resistance; D005128:Eye Diseases / Q000209:etiology / Q000601:surgery*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012507:Sarcoidosis / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D014605:Uveitis / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000473:pathology / Q000601:surgery*
chemical_list: D005938:Glucocorticoids